S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)

Azenta (AZTA) Stock Price, News & Analysis

$62.71
-1.40 (-2.18%)
(As of 12:08 PM ET)
Today's Range
$62.53
$63.74
50-Day Range
$60.46
$67.51
52-Week Range
$36.01
$69.16
Volume
163,100 shs
Average Volume
367,383 shs
Market Capitalization
$3.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.67

Azenta MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
16.5% Upside
$74.67 Price Target
Short Interest
Bearish
7.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.68mentions of Azenta in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
96.15%
From $0.26 to $0.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.92 out of 5 stars

Medical Sector

1399th out of 1,856 stocks

Special Industry Machinery, Not Elsewhere Classified Industry

19th out of 26 stocks

AZTA stock logo

About Azenta Stock (NASDAQ:AZTA)

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

AZTA Stock Price History

AZTA Stock News Headlines

5 medical stocks growing earnings by triple digits (AZTA)
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning
Strong Buy Rating for Azenta, Inc. Amid Growth and Strategic Initiatives
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Azenta: Q1 Earnings Insights
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Preview: Azenta's Earnings
Natural gas utility Spire names new chairman
Azenta to Host Investor Day on March 14, 2024
Politan Capital Management LP Bolsters Stake in Azenta Inc
Recap: Azenta Q4 Earnings
See More Headlines
Receive AZTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Azenta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
2/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Special industry machinery, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:AZTA
Employees
3,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.67
High Stock Price Target
$79.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+16.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-14,260,000.00
Pretax Margin
-4.75%

Debt

Sales & Book Value

Annual Sales
$665.07 million
Cash Flow
$1.63 per share
Book Value
$43.82 per share

Miscellaneous

Free Float
54,778,000
Market Cap
$3.57 billion
Optionable
Optionable
Beta
1.56
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Stephen S. Schwartz (Age 65)
    CEO, President & Director
    Comp: $1.05M
  • Mr. Robin Vacha (Age 48)
    Senior Vice President of Global Operations
    Comp: $533.35k
  • Mr. Jason W. Joseph (Age 53)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $544.13k
  • Mr. Herman Cueto (Age 50)
    Executive VP & CFO
  • Ms. Violetta Hughes (Age 52)
    VP & Chief Accounting Officer
  • Mr. Michael Paulo
    VP and Chief Information & Digital Officer
  • Sara Silverman
    Head of Investor Relations & Corporate Communications
  • Mr. John E. O'Brien (Age 54)
    Senior Vice President of Corporate Development
  • Ms. Olga Pirogova (Age 50)
    Senior VP & Chief HR Officer
  • Mr. J. Robert Woodward
    Senior Vice President of Global Quality & Regulatory














AZTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Azenta stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Azenta in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AZTA shares.
View AZTA analyst ratings
or view top-rated stocks.

What is Azenta's stock price target for 2024?

4 brokerages have issued twelve-month price targets for Azenta's stock. Their AZTA share price targets range from $70.00 to $79.00. On average, they predict the company's share price to reach $74.67 in the next twelve months. This suggests a possible upside of 16.5% from the stock's current price.
View analysts price targets for AZTA
or view top-rated stocks among Wall Street analysts.

How have AZTA shares performed in 2024?

Azenta's stock was trading at $65.14 at the beginning of 2024. Since then, AZTA shares have decreased by 1.6% and is now trading at $64.11.
View the best growth stocks for 2024 here
.

Are investors shorting Azenta?

Azenta saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 4,230,000 shares, an increase of 7.4% from the January 15th total of 3,940,000 shares. Based on an average daily trading volume, of 469,100 shares, the short-interest ratio is presently 9.0 days. Currently, 7.7% of the company's stock are sold short.
View Azenta's Short Interest
.

When is Azenta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AZTA earnings forecast
.

How were Azenta's earnings last quarter?

Azenta, Inc. (NASDAQ:AZTA) released its quarterly earnings data on Monday, November, 13th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.12. The business had revenue of $165.95 million for the quarter, compared to analysts' expectations of $163.91 million. Azenta had a negative net margin of 2.92% and a positive trailing twelve-month return on equity of 0.49%. The business's quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the company earned $0.16 earnings per share.

What guidance has Azenta issued on next quarter's earnings?

Azenta issued an update on its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided EPS guidance of 0.190-0.290 for the period, compared to the consensus estimate of 0.250. The company issued revenue guidance of $696.0 million-$718.0 million, compared to the consensus revenue estimate of $703.3 million.

Who are Azenta's major shareholders?

Azenta's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.13%), Dimensional Fund Advisors LP (4.01%), Norges Bank (3.88%), Allspring Global Investments Holdings LLC (2.97%), GW&K Investment Management LLC (2.76%) and Conestoga Capital Advisors LLC (2.32%). Insiders that own company stock include David C Gray, Jesus Linda De, Kimberly Crowley, Lindon G Robertson and Matthew Mcmanus.
View institutional ownership trends
.

How do I buy shares of Azenta?

Shares of AZTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AZTA) was last updated on 2/21/2024 by MarketBeat.com Staff

From Our Partners